Battling Cancer THEME

1175.81 -23.16 (-1.97%) Sell

Optimize theme

BATTLINGCANCER THEME investors disappointed by market underperformance

14 min read

Battling Cancer ranked among the worst performers on Tuesday. It returned -1.97% to close at 1175.81. On a day when the overall market breadth was 34%, it closed higher than 77% of the market. In comparison, the benchmark SP500 index closed today at +0.01%.

[Theme constituents]

~BATTLINGCANCER is currently in a down trend. Over the last three months 2 bearish signals have generated a profit of +18.93% for investors.


~BATTLINGCANCER has been underperforming the SP500 index in recent time, after having outperformed till 28 Sep, 2018. Over the last 1 year and 6 months, ~BATTLINGCANCER outperformed the SP500 index on 53% days.

During the last three months ~BATTLINGCANCER was mostly loss making and delivered on average -0.4% per day. It's best return during this period (of +4.05%) was on Wednesday, 31 Oct, 2018. While it's worst loss in the same period (of -6.13%) was on Wednesday, 24 Oct, 2018. There was initially a bearish trend during this period which started on 1 Oct, 2018 and went on till 8 Oct, 2018. The trend delivered -6.96% losses to investors. This was followed by a bullish trend that started on 30 Oct, 2018 and ended on 5 Nov, 2018. This bullish trend delivered +9.66% to investors.

On monthly basis, ~BATTLINGCANCER delivered profits in more months over the last year, than losses. ~BATTLINGCANCER delivered profits less regularly than SP500 index. ~BATTLINGCANCER was also a more risky investment than SP500 index as it's worst month in the last year, Oct 2018, returned -15.07% compared to -7.75% returned by SP500 index in Dec 2018. ~BATTLINGCANCER and SP500 index, both had periods of 6 consecutive profitable months. It is interesting to note that both ~BATTLINGCANCER and SP500 index significantly outperform during months when quarterly/annual results are announced.

If you do chose to invest in a share, invest for the lifetime.
-- Sandeep Sahajpal

~BATTLINGCANCER is becoming less volatile overall. In comparison, the SP500 index is seeing a rise in volatility. During the last three months, there was a significant surge in ~BATTLINGCANCER's volatility from 1 Oct, 2018 to 1 Nov, 2018. While there was a significant surge in the SP500 index's volatility from 19 Sep, 2018 to 29 Oct, 2018.

Advanced/professional short-term investors should note that ~BATTLINGCANCER has significant positive skewness in it's return distribution. This indicates that investors can expect ~BATTLINGCANCER to recover from drawdowns quickly. Which makes ~BATTLINGCANCER a good candidate for investing on short-term bullish trends or even counter-trends hoping for a pull-back.

~BATTLINGCANCER has more chance of extreme outcomes than the SP500 index. Therefore, ~BATTLINGCANCER must receive a lower allocation than SP500 in your portfolio. SP500 index usually has shorter drawdown period than ~BATTLINGCANCER.

On a general note (since you are interested in ~BATTLINGCANCER), two instruments that have been extremely volatile in recent times are OPNT and IX. Investors in these instruments should consider reducing their exposure (to OPNT and IX) and diversifying their portfolios.

Want to improve your Portfolio's performance?

Spotalpha's Portfolio optimizer is all you need to improve your returns and reduce your risk.
Optimize Portfolio NOW
Symbol Price {{retType}} | Tr.
{{detail.symbol}} {{detail.close}} {{detail.priceChange}}  {{detail.pctChange}}%  {{}} {{detail.trend}} 
If you liked what you read here ...

... we have a small favour to ask. Help us bring the power of algorithmic trading strategies to individual investors.

All content in this article was automatically generated by algorithms. This ensures that there are no human biases in the analysis provided. This approach to investing is not new and has been around for more than three decades. Yet, it has been available to only the most affluent or elite investors leaving individual investors to trade on emotions (such as fear and greed), intuition and poor analysis from third-parties. We want to change this.

We want to empower investors with all the tools and analysis required by them to make a rational investment decision.

If you found Spotalpha useful, consider making a contribution. For as little as $5 you can support our efforts and it takes less than a minute. Thank you. Contribute
Share with friends   WhatsApp   Facebook   Twitter